Medunik USA

What Medunik USA does

Medunik USA, Inc. is a U.S. specialty pharmaceutical company that commercializes FDA-approved orphan drugs for Americans with rare diseases, operating as a wholly-owned subsidiary of the Canadian Duchesnay Pharmaceutical Group (DPG), headquartered in Princeton, New Jersey. Its portfolio consists of two core products: Siklos (hydroxyurea), approved in 2017 and the only FDA-approved dissolvable formulation of hydroxyurea, indicated for sickle cell disease in patients aged 2 and older, available in scored 100 mg and triple-scored 1,000 mg tablets enabling 50 mg dosing increments; and Pheburane (sodium phenylbutyrate), launched in the U.S. in September 2022 as a taste-masked coated pellet formulation for the chronic management of urea cycle disorders involving CPS, OTC, or AS deficiencies. Both products are commercialized under inbound licensing arrangements (Siklos from Theravia SAS; Pheburane from Lucane Pharma), so Medunik USA's role is U.S. registration, distribution, and commercialization rather than drug discovery.

The company's business model is prescription pharmaceutical sales reimbursed through a multi-payer mix including 39 state Medicaid programs and Tricare for Siklos, ~80% of commercial insured lives and 18-19 preferred state Medicaid formularies for Pheburane, with dispensing handled through specialty pharmacy partners Accredo Health Group and CVS Specialty under the UNIK Support Program. Patient support services — copay assistance, patient assistance for uninsured patients (effective price as low as $0), clinical coordinator outreach, a Quick Start & Bridge program, and mail-order pharmacy — function as both a commercial lever and a market-access moat. Go-to-market is enterprise field sales targeting healthcare providers and payers, supported by product-specific consumer and HCP websites (SiklosUSA.com, Pheburane.com) and PR-driven coverage expansion announcements. The company is small (1-10 employees per the careers page), holds no external funding, and does not disclose revenue.

Name

Medunik USA

Legal name

Medunik USA, Inc.

Website

https://medunikusa.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals (Orphan Drugs)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Rare Renal & Nephrology Disorder Therapies (HLAIAIAI)

Keywords

• Orphan drugs
• Rare disease therapeutics
• Specialty pharmaceuticals
• Sickle cell treatments
• Urea cycle disorder therapy

Headquarters

HQ city

Princeton

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Marketing or Sales, Supply Chain, Operations, Technology or R&D, Infrastructure

Revenue model

1. Prescription Pharmaceutical Sales: Medunik USA generates revenue through the sale of prescription orphan drugs to patients with rare diseases. The company distributes Siklos (hydroxyurea) for sickle cell disease and Pheburane (sodium phenylbutyrate) for urea cycle disorders through pharmacy channels, with reimbursement from Medicaid, commercial insurance, and other payer programs.

Pricing tiers

Go-to-market motion2 records

Distribution channels6 records

Marketing channels5 records

Core offering

Medunik USA commercializes two FDA-approved orphan drugs in the U.S.: Siklos (hydroxyurea), the only FDA-approved dissolvable formulation of hydroxyurea for sickle cell disease, and Pheburane (sodium phenylbutyrate), a taste-masked coated-pellet formulation for chronic management of urea cycle disorders. The company acquires these products via exclusive licensing and development partnerships with Theravia SAS and Lucane Pharma, and supplements them with the UNIK Support Program providing copay and patient assistance, clinical coordinator outreach, and mail order pharmacy fulfillment through Accredo and CVS Specialty.

Product overview

Medunik USA is a specialty pharmaceutical company dedicated to providing Americans with rare diseases access to orphan drugs. The company operates as part of Duchesnay Pharmaceutical Group and focuses on two core therapeutic areas: Hematology (Siklos® for sickle cell disease) and Urea Cycle Disorders (Pheburane® for UCDs). Medunik USA's portfolio consists of two FDA-approved prescription medications—Siklos® (hydroxyurea) for sickle cell disease and Pheburane® (sodium phenylbutyrate) for urea cycle disorders—complemented by the UNIK Support Program that provides comprehensive patient assistance services including clinical coordination, copay support, and specialty pharmacy services.

Differentiator

Problem solved

Functional benefit

Products and services

• Siklos (hydroxyurea) FDA-approved prescription orphan drug for sickle cell disease, indicated to reduce the frequency of painful crises and the need for blood transfusions in adults and pediatric patients 2 years of age and older with sickle cell anemia with recurrent moderate to severe painful crises. Available as scored 100 mg and triple-scored 1,000 mg dissolvable tablets enabling flexible body-weight dosing in 50 mg increments.
• Pheburane (sodium phenylbutyrate) FDA-approved prescription orphan drug used as adjunctive therapy to standard of care, including dietary management, for the chronic management of urea cycle disorders (UCDs) involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinate synthetase (AS) in adult and pediatric patients. Delivered as very small taste-masked coated oral pellets about the size of sugar crystals to improve palatability and adherence.
• UNIK Support Program Comprehensive patient support program accompanying Siklos and especially Pheburane, providing Clinical Coordinator Outreach, Copay Assistance and Patient Assistance Programs (eligible uninsured patients may pay as little as $0), Mail Order Pharmacy Services through Accredo Health Group and CVS Specialty, and a Quick Start & Bridge Program that delivers product while insurance approvals are pending.

Quantifiable outcome

• Siklos reduces the frequency of painful crises and reduces the need for blood transfusions in patients with sickle cell anemia with recurrent moderate to severe painful crises
• +3 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature3 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Lucane PharmacoreStrategic or Co-development Partner · 1 September 2022Pheburane was developed by Lucane Pharma and is under exclusive distribution in the U.S. through Medunik USA. The product has been available in Europe since 2013 and Canada since 2015, demonstrating globally its effectiveness in the treatment of urea cycle disorders.
• Accredo Health GroupcoreChannel Partner/ Reseller/ DistributorAccredo Health Group is one of two specialty pharmacy partners in Medunik USA's UNIK Support Program for Pheburane, providing mail order pharmacy services for patients.
• CVS SpecialtycoreChannel Partner/ Reseller/ DistributorCVS Specialty is one of two specialty pharmacy partners in Medunik USA's UNIK Support Program for Pheburane, providing mail order pharmacy services for patients.
• Viking Healthcare SolutionsminorImplementation/ SI/ Consulting PartnerViking Healthcare Solutions has provided market access and commercialization services to Medunik USA for Pheburane, supporting pricing strategy and healthcare system cost-savings efforts.
• Duchesnay Pharmaceutical GroupcoreOthersMedunik USA is part of Duchesnay Pharmaceutical Group (DPG), headquartered in Blainville, Quebec, Canada. DPG consists of six pharmaceutical companies including Medunik Canada and Medunik USA providing treatments for rare diseases, Duchesnay and Duchesnay USA for women's health, and Analog Pharma specializing in orphan generic medications.
• Theravia SAScoreOEM/ Whitelabel/ Licensing PartnerSiklos is a registered trademark owned by Theravia SAS and used under license by Medunik USA. Siklos is the only FDA-approved dissolvable formulation of hydroxyurea for sickle cell disease.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Sobi (Swedish Orphan Biovitrum): European-headquartered orphan drug specialist that commercializes rare-disease treatments (hematology, immunology, metabolic) globally, mirroring Medunik's strategy of bringing differentiated rare-disease therapies to underserved patient populations.
• Immedica Pharma: Pan-European specialty pharma focused on commercialization of late-stage rare-disease assets, with growing US presence — same asset-light licensing-and-distribute model as Medunik USA for orphan drugs.
• Recordati Rare Diseases: Specialty division of Recordati focused on acquiring and commercializing orphan drugs for the US market — virtually identical business model to Medunik USA of licensing/importing niche rare-disease therapies from international developers and selling through specialty pharmacy and Medicaid channels.
• Emmaus Life Sciences: US specialty pharmaceutical company commercializing Endari (L-glutamine) for sickle cell disease — directly competes with Siklos in the same rare hematology indication and Medicaid/commercial reimbursement channels.
• Global Blood Therapeutics (Pfizer): Acquired by Pfizer for Oxbryta (voxelotor) and other sickle cell disease therapies — competes head-to-head with Siklos for the same ~100K US sickle cell patient population through specialty distribution and payer channels.

Emerging players

• Vertex Pharmaceuticals: Recently received FDA approval for Casgevy, the first CRISPR-based sickle cell disease therapy — emerging disruptive threat in Medunik USA's core sickle cell indication that could shift patient flow away from chronic hydroxyurea therapy.
• Acer Therapeutics / RELIEF THERAPEUTICS: Markets OLPRUVA, an alternative sodium phenylbutyrate formulation for urea cycle disorders — competing with Pheburane in the same indication and leveraging similar specialty pharmacy distribution channels.

Broad incumbents

• BioMarin Pharmaceutical: Large rare-disease-focused biopharma with an extensive orphan drug portfolio in metabolic, hematology and CNS — relevant comparable on rare-disease commercial infrastructure and Medicaid/PDL coverage dynamics.
• Alexion Pharmaceuticals (AstraZeneca Rare Disease): AstraZeneca's rare-disease unit, the largest US-focused orphan drug franchise (Soliris, Ultomiris, Strensiq) — directly comparable on commercial scale, Medicaid penetration strategy, and specialty pharmacy partnerships for ultra-rare therapies.
• Ultragenyx Pharmaceutical: Established rare-disease biopharma with multiple FDA-approved orphan drugs across metabolic and neurologic indications — comparable rare-disease commercial focus but with proprietary development rather than licensing model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/medunik-usa
• Xx.com/medunikusa

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medunik USA